C
Conghua Xie
Researcher at Wuhan University
Publications - 282
Citations - 5918
Conghua Xie is an academic researcher from Wuhan University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 30, co-authored 230 publications receiving 3999 citations.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.
TL;DR: This cross-sectional study reviews the medical records of 1524 patients with cancer treated at a single tertiary care hospital in Wuhan, China to evaluate the characteristics associated with transmission of the SARS-CoV-2 virus.
Journal ArticleDOI
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.
Humaid O. Al-Shamsi,Waleed Alhazzani,Ahmad Alhuraiji,Eric A. Coomes,Roy F. Chemaly,Meshari Almuhanna,Robert A. Wolff,Nuhad K. Ibrahim,Melvin L.K. Chua,Sebastien J. Hotte,Brandon M. Meyers,Tarek Elfiki,Giuseppe Curigliano,Cathy Eng,Axel Grothey,Conghua Xie +15 more
TL;DR: The potential challenges associated with managing cancer patients during the COVID‐19 infection pandemic will be addressed, with suggestions of some practical approaches.
Journal ArticleDOI
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Yunpeng Yang,Zhehai Wang,Jian Fang,Qitao Yu,Baohui Han,Shundong Cang,Gongyan Chen,Xiaodong Mei,Zhixiong Yang,Rui Ma,M. Bi,Xiubao Ren,Jianying Zhou,Baolan Li,Yong Song,Jifeng Feng,Juan Li,Zhiyong He,Rui Zhou,Weimin Li,You Lu,Yingyi Wang,Lijun Wang,Nong Yang,Yan Zhang,Zhuang Yu,Yanqiu Zhao,Conghua Xie,Ying Cheng,Hui Zhou,Shuyan Wang,Donglei Zhu,Wen Zhang,Li Zhang +33 more
TL;DR: In Chinese patients with previously untreated locally advanced or metastatic nonsquamous NSCLC, the addition of sintilimab to chemotherapy of pemetrexed and platinum resulted in significantly longer PFS than that of chemotherapy alone with manageable safety profiles.
Journal ArticleDOI
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Zi-Xian Wang,Chengxu Cui,Jun Yao,Yanqiao Zhang,Mengxia Li,Jifeng Feng,Shujun Wang,Yun Fan,Jian Hua Shi,Lizhi Zhang,Lin Shen,Yongqian Shu,Cailian Wang,Tian-yang Dai,Teng Mao,Long Chen,Zengqing Guo,Bo Liu,Hongming Pan,Shundong Cang,Yi Jiang,Junye Wang,Min Ye,Zhendong Chen,Da Jiang,Qin Lin,Wei Ren,Junsheng Wang,Lin Wu,Yong Xu,Zhanhui Miao,Meili Sun,Conghua Xie,Ying Liu,Qifeng Wang,Lina Zhao,Canhong Huang,Ke Jiang,Kunyu Yang,Dao-Rui Li,Yunpeng Liu,Zhitu Zhu,Ri Shu Chen,Liqun Jia,Wei Liu,Wangjun Liao,Hong-Xu Liu,Dai-Yuan Ma,Jie Ma,Yanru Qin,Zhi-xiang Shi,Qichun Wei,Ke Xiao,Yan Zhang,Ying Zhang,Xin Chen,Guanghai Dai,Jianxing He,Junhe Li,Guanghui Li,Yong Li,Zhihua Liu,Xianglin Yuan,Junping Zhang,Zhichao Fu,Yifu He,Fang Ju,Zheng Liu,Peng Tang,Tie-Jun Wang,Weibo Wang,Jing Zhang,Xianming Luo,Xiongwen Tang,Rena J. May,Hui Feng,Sheng Yao,Patricia Keegan,Rui-Hua Xu,Feng Wang +79 more
TL;DR: Toripalimab plus TP significantly improved progression-free survival (PFS) and overall survival (OS) in patients with treatment-naïve, advanced esophageal squamous cell carcinoma (ESCC) with a manageable safety profile as mentioned in this paper .
Journal ArticleDOI
Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma.
Liang Chen,Lushun Yuan,Yongzhi Wang,Gang Wang,Yuan Zhu,Rui Cao,Guofeng Qian,Conghua Xie,Xuefeng Liu,Yu Xiao,Xinghuan Wang +10 more
TL;DR: Using weighted gene co-expression analysis, FCER1G was identified and validated in association with ccRCC progression and prognosis, which might improve the prognosis by influencing immune-related pathways.